The process of antigen recognition depends in part on the amount ofpeptide antigen available and the affinity of the T cell receptor for a particular peptide-major histocompatibility complex (MHC) molecule complex. The availability of self antigen is limited by antigen processing, which is compartmentalized such that peptide antigens presented by MHC class I molecules originate in the cytoplasm, whereas peptide antigens presented by MHC class II molecules are acquired from the endocytic pathway. This segregation of the antigen-processing pathways may limit the diversity of antigens that influence the development and selection of, e.g., CD4-positive, MHC class II-specific T cells. Selection in this case might involve only a subset of self-encoded proteins, specifically those that are plasma membrane bound or secreted.
eral requirements to affect a state of self tolerance. They must be available for processing and loading onto MHC class I and class II molecules, and they must be processed to peptides that bind and stabilize MHC molecules.
Exogenous and cell surface-associated antigens gain access to the endocytic compartment, where they are degraded and associate with MHC class II (1) (2) (3) (4) . These MHC class IIpeptide complexes are most often recognized by CD4-positive helper T cells. Peptides from endogenous proteins are usually presented on MHC class I and most often recognized by CD8-positive T cells. Most antigens seem to follow this rule. An increasing body of data produced in in vitro systems shows, however, that proteins synthesized intracellularly in APC may also associate with MHC class II 1Abbreviations used in this paper: DP, double positive; ePCC, endogenous form of PCC; mPCC, membrane-associated PCC; PCC, pigeon cytochrome c; PPD, purified protein derivative; SP, single positive. (2, 3, (5) (6) (7) (8) (9) (10) (11) (12) . It therefore seems that cytosolic proteins can also gain access to the MHC class II compartment through pathways that are incompletely characterized. One pathway proposed is autophagy, and this may drive cytosolic components into the late endosomal or lysosomal compartments (13, 14) . Another possibility is that endogenous antigens may be directed to the class II pathway in phagocytic cells via the engulfment of apoptotic cells. The relevance of such "alternative" pathways in T cell development is not well characterized, but is of considerable importance since this would mean that endogenous proteins can shape the Th repertoire.
To address these questions, we generated two transgenic mouse lines that express pigeon cytochrome c (PCC) endogenously (ePCC) or on the cell surface (mPCC) in the thymus. Cytochrome c is normally synthesized in the cytosol and is targeted into the intermembrane space, where it will complex with the respiratory chain proteins located on the inner mitochondrial membrane (15) . Using an H-2K b promoter construct, we expressed PCC representing a cytosolic/mitochondrial neo-self antigen in the thymus of transgenic mice. For comparison, PCC was altered by replacing the amino-terminal 19 amino acids with the leader/ transmembrane signal anchor sequence from the influenza hemagglutinin type II membrane protein. We predicted that this modification would yield a type II membrane-bound protein on the cell surface and on the inside of an endosomal vesicle. Using these mice together with transgenic mice expressing a TCR specific for PCC peptide 88-104, we analyzed the induction of Th tolerance.
A second issue in the induction of tolerance concerns the timing of deletion. In some models of negative selection, the developing T cells are deleted as early DP thymocytes in the proximal cortex, whereas in other models, the deletion occurs later at the DP to single-positive (SP) stage when the cells are at the cortical-medullary junction. One possibility is that the affinity of the interaction between the TCR and the MHC-peptide complex determines the time point of deletion. Using another PCC-specific TCR transgenic mouse line that expresses a receptor with a reduced affinity, we were able to directly test and visualize the avidity model of negative selection in vivo.
Materials and Methods
Transgenic Mice. The synthetic PCC gene was a generous gift from Dr. F. Sherman (University of Rochester, Rochester, NY) (16) . It was cloned as a BamHI fragment into the expression vector pES4 (reference 17 and Fig. 2 ). Vector sequences were removed by a NotI/XhoI digest. Injection of this construct into (C57BL/6 SJL) oocytes yielded the SPK (ePCC) line, which was established to have integrated the PCC gene only on one chromosome. The second PCC construct targeted PCC to the cell surface by replacing the NH2-terminal mitochondrial targeting sequence with the influenza neuraminidase type II signal anchor (a kind gift from Dr. D. Donaghue, University of California, San Diego). The modified PCC gene was cloned as a BamHI fragment into pES4, and vector sequences were removed by a ClaI/ NotI digest. The RO (mPCC) founder line was chosen for further investigation. Transgenic offsprings were identified by Southern analysis of tail biopsies. AD10 and AND TCR transgenic mice have been described previously (17, 18) .
Northern Analysis. Northern blots were performed as described by Maniatis et al. (19) . Total RNA was extracted from the tested tissues using TRIZOL reagent (GIBCO BRL, Gaithersburg, MD), and 20 b~g/lane was resolved through agarose/formaldehyde denaturing gels. Autoradiographs were exposed for 8 h. LPS blasts were prepared by incubating spleen cells in Click's EHAA medium supplemented with 10 -6 M 2-ME, penicillin/streptomycin, glutamine, 10% FCS, and 20 p,g/m] LPS for 48 h. Blast cells were then purified over a Ficoll gradient.
lmmunofluorescence Microscopy. Correct cellular localization of the transgenes was confirmed by transient transfection of Cos7 and HeLa cells with FLAG-tagged PCC gene variants: The 5' end of both PCC gene variants were modified using appropriate PCK primers to clone the genes in frame into the multiple cloning site of the plasmid pCMV-FLAG-2c (Eastman Kodak Co., Rochester NY). This resulted in the NH2-terrninal addition of a DYKD-DDDK peptide FLAG tag that could be detected with the mAb M2 (Kodak). Transcription was driven by the human CMV promoter. Cells were grown on cover slides for 24 h in six-well plates and transfected with Lipofectamine (GIBCO BRL). After a total incubation time of 48 h, the cells were fixed with 95% ethanol/5% acetic acid, and FLAG-tagged protein was detected using the mAb M2 and secondary FITC-labeled goat anti-mouse antibodies (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).
Proliferation Assays. For secondary in vitro assays, 50 p~g of PCC protein (Sigma Immunochemicals, St. Louis) emulsified in CFA were injected into one hind foot pad. After 7 d, the draining popliteal and inguinal lymph nodes were collected and minced into a single-cell suspension. 3-5 • 105 nylon wool-enriched T cells were cocultured in Click's EHAA medium supplemented with 10 -6 M 2-ME, penicillin/streptomycin, glutamine, and 10% FCS. As a source ofAPCs, 5 • 106 irradiated (3,500 fads) B10.A spleen cells were added. APC were pulsed with the indicated doses ofPCC peptide 88-104 or with 50 I.Lg/ml purified protein derivative (PPD) to control for priming. After 3 d, 1 p, Ci [3H]thymidine was added to the cultures and incubated for another 16 h. Cells were harvested, and the incorporated radioactivity was counted on a liquid scintillation [3 counter .
FACS ~ Analysis. Stainings were performed in PBS containing 2% FCS, 0.1% sodium azide, and 10 mM EDTA using the following antibodies: anti-CD4 PE, anti-CD8 FITC, and anti-CD8 tricolor (all from Caltag Laboratories, San Francisco, CA). Transgenic TCR chains were detected with KJ25 (anti-V[33 [20] ) and RR8 (anti-Veil1; a generous gift from Dr. O. Kanagawa, Washington University, St. Louis, MO) culture supernatants. FITC-conjugated goat anti-hamster (for KJ25) and goat anti-rat (for RIK8) were used as second stage antibodies. 10,000 live cells were collected on a FACScan | (Becton Dickinson & Co., Mountain View, CA) and analyzed using CellQuest software (Becton Dickinson & Co.).
In Situ TUNEL Assays. TUNEL assays were performed as described previously (21) . Briefly, thymi were embedded in OCT (Miles, Inc., Kanakee, IL) and frozen tissue sections were prepared onto microscope slides, dried for 2 d at 4~ fixed in acetone, and endogenous peroxidase was quenched by incubation in 0.01% H202, 50 mm Tris buffer, 150 mM NaCI. After washing, digoxigenin-labeled dUTP (Boehringer Mannheim Corp., Indianapolis, IN) was incorporated into DNA strand breaks using terminal deoxynucleotidyl transferase (TdT; Promega, Madison, WI). Apoptotic cells were detected with sheep Fab antidigoxigenin (Boehringer Mannheim) followed by incubation with peroxidase-coupled rabbit anti--sheep IgG F(ab)2-specific antibodies (Jackson ImmunoResearch). Sections were developed with amino-ethyl-carbazol solution and counterstained with Meyer's hematoxylin.
In Situ Hybridization. In situ hybridizations were prepared exactly as described previously (22) . 3SS-labeled antisense and sense riboprobes were transcribed from both directions using the PCC gene cloned into pBluescript SK II. Frozen sections were hybridized with the sense and antisense riboprobes. Exposures were performed at 4~ in the dark for 2 wk before development.
Bone Marrow Chimeras. Bone marrow was collected from the tibia and femur of donors and in vitro-depleted ofT cells by two rounds of treatment with T24 (anti-Thyl) antibody plus complement. 1-2 • 107 bone marrow cells were injected intravenously into irradiated (1,050 rads) recipients. Recipients were previously injected with 200 I_tg i.p, ofPK136 (anti-NKl.1) ammoniumsulfate-precipitated ascites fluid 3 and 1 d before transfusion. Animals were left for reconstitution for the indicated amounts of time with 25 mg/liter neomycin sulfate and 13 mg/liter polymyxin B sulfate supplemented to their drinking water for the first 3 wk. Chimerism of mixed bone marrow chimeras was determined after 3-4 wk by collecting blood from the tail vein into FACS ~ buffer.
Samples were stained with anti-B220-PE and anti-I-E-FITC (both from Caltag). After incubation, red cells were lysed and the degree of chimerism was determined by gating on B220-positive live B cells and monitoring the expression of H-2E.
Results

Generation of Intracellular and Cell Membrane-associated, PCC-transgenic Mice.
The wild-type PCC transgene was expressed in lymphoid tissues, including the thymus, using the pES4 expression vector (Fig. 1) . A second construct was generated to target PCC to the cell surface: the mitochondrial targeting sequences are located at the amino terminal end and within the protein (15, 23) . The NH2-terminal mitochondrial targeting sequence was replaced with the influenza neuraminidase type II signal anchor. This modified PCC gene was also cloned into the H-2K b expression vector. SPK mice had integrated the ePCC whereas R O mice were transgenic for mPCC. Northern Blot analysis revealed that the transgenes were expressed in thymus, spleen, and LPS-stimulated B cells (Fig. 2) . mPCC mice expressed significantly higher m R N A levels than ePCC mice. Transgenic mRNA was readily detected in LPS blasts and in spleens of ePCC mice after prolonged exposure overnight (not shown).
Cellular Localization. All the antibodies we tested crossreacted on mouse cytochrome c, thus preventing us fi'om direcdy examining the intracellular localization of transgenic PCC expression. To circumvent this problem, we generated constructs in which the FLAG tag was fused to the N H 2-terminal end of the two PCC variants. Cos7 cells (Fig. 3 ) and HeLa cells (data not shown) were transiently tranfected and analyzed by fluorescence microscopy using the FLAGspecific mAb M2. The staining pattern of FLAG-tagged mPCC-transfected cells was consistent with localization to the cell surface and to an intracellular organelle ( Transgenic PCC mP, NA expression. Total RNA from thymus, spleen, and LPS blasts obtained from ePCC, mPCC, and nontransgenic control mice was analyzed by Northern blot. To confirm that equal amounts of total RNA were loaded in each lane, the filters were reprobed with a glyceraldehyde 3-phosphate dehydrogenase-specific probe.
to a punctate pattern of staining that is typical ofmitochondrial localization patterns for ethanol-fixed cells (Fig. 3 B) . Thus, the gene products were targeted to the anticipated cellular sites.
Induction of Tolerance in mPCC and ePCC Mice.
To investigate whether both forms of PCC were able to induce tolerance, proliferative responses to PCC were measured in secondary in vitro cultures. PCC-transgenic mice and control httermates were inoculated with PCC protein emulsified in CFA, and enriched T cells from the draining lymph nodes were explanted to tissue culture 7 d later. Cultures were stimulated with various concentrations of PCC peptide or a single dose of PPD. Proliferation was greatly reduced in ePCC mice and comparable to background levels in mPCC mice (Fig. 4) . The response to PPD was equivalent in PCC-transgenic and control mice (see Fig. 4 legend) . Thus, ePCC and mPCC were both effective at inducing a state of tolerance. The quantitative difference in the degree of responsiveness presumably resulted from the amount of expressed antigen-MHC complexes on the surface of APCs. We could not determine whether this resulted from the difference in intracellular localization, the level of expressed antigen, or both.
To determine the stage of tolerance induction in the two PCC-transgenic mouse hnes, they were crossed with AD10 TCR. transgenics that bear a receptor specific for PCC peptide 88-104 on H-2E k (17, 18) . Comparison ofthymocytes from AD10• double transgenics with AD10 single transgenic animals revealed that expression of both forms of PCC resulted in a largely reduced population of CD4 SP thymocytes (Fig. 5) . Transgenic V0tl I and V133 TCP, chain expression levels were unaltered on the DP populations (data not shown); however, the CD4 SP thymocytes that escaped clonal deletion displayed biphasic and somewhat reduced patterns of staining for Votl 1 and V [33 (Fig. 5) . This is indicative of cells that express endogenous T cell receptor chains. It is even possible that all of the CD4 SP thymocytes express at least one nontransgenic T C R chain. When analyz- site of deletion, we determined where in the thymus selfreactive thymocytes were eliminated. In situ TUNEL assays performed on thymi of double transgenic mice to detect apoptotic thymocytes showed that cells which had fragmented their DNA appeared in the cortex of early deleting mPCC mice, whereas such cells were found at the corticomedullary junction and in the medulla of late deleting ePCC mice (Fig. 6, A and B) . Thus, relatively early deletion of DP correlated with cortical apoptosis, whereas late deletion paralleled with cortico-medullary and medullary apoptosis.
To determine the anatomical location of PCC expression within the thymus, in situ hybridization studies were carried out using a PCC-specific probe on thymic sections, Fig. 7 A-C depicts autoradiographic sections showing that PCC is expressed in the cortex and medulla of both PCCtransgenic mouse lines, albeit at lower levels in ePCC mice. Since thymocytes also express the transgenes, part of the signal seen in this experiment probably originates from thymocytes that presumably do not directly function as APCs. To address this issue further, mPCC and ePCC-transgenic mice were lethally irradiated and reconstituted with bone marrow from normal mice. These mice were analyzed after 4 wk and typed for chimerism. In the thymus of these radiation chimeras, the only cells that could express a PCC transgene message would be epithelial cells and some radioresistant macrophages. The expression patterns were identical to those of unmanipulated transgenic animals. As expected, however, the overall signal was reduced (data not shown). Compared to the cortical expression levels, medunary expression was lower in both lines and experiments. Thus, at least for the unmanipulated thymus and the radioresistant cells of the thymus, there was no anatomical difference in the expression of ePCC and mPCC.
The above results argue for the second possibility that the level of antigen expression can account for early vs. late deletion. Indeed, R.NA expression levels as determined by Northern blot analysis were higher in mPCC than in ePCC mice (see Fig. 2 ). Taken together, early deletion resulted in apoptosis in the cortex and the medulla, whereas late deletion promoted the elimination of thymocytes at the cortico-medullary junction and in the medulla. Presumably, the time point of deletion was influenced by the levels of PCC-bound MHC class II molecules.
Influence of TCR Affinity on Time Point and Site of Deletion.
Our results are consistent with the process of negative selection depending in part on the level of antigen presentation, and thus the avidity of the interaction between the TC1L and the peptide-MHC complex. Another component that determines the avidity of the interaction between the TCR. and the MHC-peptide complex is the affinity of the TCR itself. AND TCR-transgenic mice bear an ot chain that differs in one amino acid in the V-J junction with respect to the original AD10 receptor (17) . We have found that 70% of the AD10 DP thymocytes could be for M H C / a n t i g e n when compared with the AD10 T C R transgenics. To investigate the influence of the difference between AD10 and A N D mice on the time point and site of deletion, A N D mice were bred with m P C C mice. In such double transgenic animals, negative selection occurred very late in the DP stage (24) : deletion of DP thymocytes was marginal in A N D • mice while absolute cell numbers of the CD4 SP population were reduced by 75%. Fig. 6 C shows that apoptotic cells appeared at the corticomedullary junction in A N D • mice, and not in the cortex as in A D 1 0 X m P C C mice (see Fig. 6 A) . Thus, the self-reactive T C R expressed by a thymocyte influences the time point and site of deletion.
Endogenous Self Antigen Can be Directly Processed to Induce
Negative Selection. In principle, antigen can be processed within a cell and presented directly, or it can be acquired indirectly via engulfment of apoptotic cells (e.g., thymocytes), cellular debris, soluble shed, or secreted proteins. In particular, we were interested in determining whether ePCC is presented directly to cause negative selection. To investigate this question, the following bone marrow chimeras were generated: H-2Ek-positive ePCC, mPCC, and nontransgenic littermates were irradiated and reconstituted with H-2 b (H-2E ~ AD10 TCP,-transgenic bone marrow and analyzed 3-5 wk later (Table 1) . In these radiation chimeras, transgenic ePCC can be presented only if it is directly processed and presented by radioresistant macrophages or thymic epithelial cells. Since thymic macrophages are largely MHC class II negative (25, 26) , the most likely APC would be epithelial cells. The experiments presented in Table 1 show that the CD4 SP TCP,.-transgenic thymocyte population was significantly reduced in ePCC and mPCC recipients as compared with controls. Since we find it unlikely that epithelial cells could acquire PCC exogenously in these radiation chimeras, we deduce that ePCC can be directly processed onto MHC class II and effectively presented by thymic epithelial cells (see Discussion).
Reuptake of Self Antigen Results in Clonal Deletion.
A second set of bone marrow chimeras were tested for the possibility that PCC can be directed to the endocytic processing pathway by the reuptake of antigen derived from thymocytes undergoing apoptosis (21) or the reuptake of shed antigen. A mixture of two types of bone marrow was injected into PCC-negative, H-2Ek-positive recipients, The first type was taken from mice that expressed PCC and were H-2E knegative. This bone marrow provides PCC-transgenic thymocytes that can be engulfed and could serve as a source of shed antigen. Any APCs that develop from this bone marrow, however, will be unable to present PCC because they do not express H-2E k. The other type of bone marrow was harvested from mice that expressed H-2E k, but did not ex- *H-2Ek-positive recipients were transfused with 107 bone marrow cells obtained from AD10 TCR.-transgenic, H-2E-negative donors, and were left for reconstitution for 5 wk in experiment 1 and for 3 wk in experiment 2. *Thymocytes from recipients were stained for CD4 and CD8, and the percentages of CD4 SP thymocytes were determined by flow cytometry. Absolute cell numbers did not vary significantly.
press PCC. This bone marrow provides phagocytes that can engulf and present PCC derived from the first marrow type. Recipients expressed the MHC molecules appropriate for the presentation of PCC. After reconstitution for 8 wk, chimeras were challenged with PCC protein emulsified in CFA, and PCC-specific proliferative responses were measured in vitro. The experiment depicted in Fig. 8 shows that the presence of H-2Ek-negative, PCC-transgenic bone marrow resulted in reduced proliferative responses, regardless of whether ePCC or mPCC marrow was used. Although the degree of chimerism was lower in mice receiving mPCC marrow, the reduction in the response was comparable to ePCC chimeras, probably resulting from higher mPCC expression levels. Thus, reuptake of antigen can participate in the induction of Th tolerance. This issue was alternatively addressed by producing a similar set of chimeric mice in which all the T cells expressed the AD10 TCR. Tolerance induction could thus be monitored by flow cytometry. Table 2 shows that two out of four recipients that had received ePCC bone marrow showed some reduction in the percentage of CD4 SP thymoctes 5 wk after reconstitution. All recipients that were transfused with mPCC bone marrow showed a small but significant reduction in the CD4 SP population. We interpret these experiments to indicate that reuptake of cell- Reduction of proliferative responses in mixed bone marrow chimeras. Lymph node cells from mixed bone marrow chimeras that had been left for reconstitution for 8 wk were injected into the hind footpad with PCC protein emulsified in CFA and assayed in secondary in vitro proliferation assays. Because of the low number of cells recovered, purified cells were stimulated with the one indicated dose of PCC peptide or were left unstimulated for background proliferation. Printing efficiency was determined by measuring the proliferative response to 50 I~g/ml PPD and was comparable in all mice tested, ranging from 45,000-65,000 cpm; relatively lower PPD counts did not correlate with corresponding lower PCC-specific proliferation. Points represent results from triplicate wells per mouse. Bone marrow composition and degree of chimerism are indicated. B6, C57B1/6 bone marrow (H-2E~ B/A, (C57B1/6• bone marrow (H-2Ek). tion of these experiments is that both ePCC and mPCC can be presented without secretion or reuptake. Since epithelial cells have previously been shown to mediate negative selection inefficiently (30) , the fact that we see negative seAverage lection in this experiment is highly significant.
The experiments in which reuptake was needed to present antigen indicated that representation is an inefficient means 27.5 of inducing negative selection ( (34) (35) (36) . Based on the interpretation of the experiments in this report, the most likely route of tolerance is the direct presentation of MHC class II-bound PCC by dendritic cells.
Stockinger et al. produced radiation chimeras in which pro-C5 was expressed endogenously within macrophages, but C5 was not secreted. Pro-C5 was not presented in an antigenic form associated with class II molecules. In these mice, there was no evident tolerance. Assuming that thymic macrophages also expressed pro-C5, these mice would not be expected to exhibit tolerance to C5 for two reasons: macrophages are poor in the induction of tolerance, and endogenously synthesized pro-C5 is not presented by MHC class II. Another likely explanation for the apparent discrepancy between the results presented here and those of Stockinger et al. is that mitochondrial cytochrome c and pro-C5 may simply have a different access to the class II pathway. There are numerous examples of cytoplasmic antigens that apparently gain direct access to MHC class II presentation in vitro, and this may be protein and expression level dependent (2, 3, (5) (6) (7) (8) (9) (10) (11) (12) .
The pathway of cytoplasmic or nfitochondrial antigen presentation by MHC class II molecules is thus far uncharacterized. Loss et al. have previously reported the existence of an alternative processing pathway that allows endogenously synthesized L d peptide to traffic onto MHC class II (12) . Another potential processing pathway particularly relevant to mitochondria is via the formation of autophagosomes (37, 38) . While this is a potential mechanism for transport of mitochondrial or cytoplasmic proteins into the class II pathway, most studies are consistent with an intersection of autophagosomes and lysosomes, a point in the endocytic pathway that is believed to be later than the MHC class II compartment (1).
T Helper Cell Tolerance Induction by Endogenous Antigen TCR TCR.
(TCR. X ePCC) TCR (TCR. X mPCC) TCR.
*Recipients were transfused at a ratio of 1:1 with I07 bone marrow cells from each donor and analyzed 5 wk later. Chimerism was 50:50% in all recipients and was determined as described in Materials and Methods. r were stained for CD4 and CD8, and the percentages of CD4 SP cells were determined. associated or shed self antigen can play a part, albeit possibly minor, in the induction of Th tolerance to self antigens.
Discussion
This study was aimed at investigating parameters governing the induction of Th tolerance, including the cellular localization of self antigen, toleragen expression levels, and TCR affinities, and correlating these effects with the time point and site of deletion in vivo.
The data indicate that antigen may be directed into the class II processing pathway primarily via a direct route within the presenting cells and perhaps secondarily via reuptake of apoptotic cells, cell debris, or shed antigen. In the experiment described in Table 1 , the only source of PCC are the radioresistant cells of the thymus. The PCC-transgenic mice were irradiated with 1,050 rads, and this dosage has been shown to rapidly eliminate the bone marrow-derived APC of host origin, such as dendritic cells and macrophages (27, 28) . Since there are no radioresistant follicular dendritic cells known to reside in the thymus that could trap antigen in antibody-antigen complexes, the only presenting cells remaining after irradiation that express MHC class II molecules would be epithelial cells. These epithelial cells could not harbor peptides acquired from exogenous sources before or as a consequence of irradiation for as long as 5 wk since the half life of MHC class II-peptide complexes has been shown to he 13 h (29) . Thus, the simplest interpreta-Toleragen expression levels seem to play a role in determining the developmental stage and corresponding anatomical site of thymocyte deletion. In AD10• mice, deletion occurred within the DP subset, and this correlated with an increase in apoptosis within the cortex. In contrast, deletion in AD10XePCC transgenics occtlrred later, since there was a barely detectable decrease in the number of DP thymocytes, and increased apoptosis was found only at the cortico-medullary junction. There are two possible explanations to account for this difference. One is that the levels of antigen presentation are lower in ePCC mice, and this level is only sufficient to cause deletion in late DPs when the TCP, is upregulated. A second possibility is that antigens are expressed in anatomically different sites. We felt we could eliminate the latter possibility, since in situ hybridization showed consistent expression throughout the thymus for both transgenes. We thus conclude that a difference in antigen presentation levels accounts for the results. We did not determine whether the diminished antigen presentation is caused by decreased expression, the efficiency of the presentation pathway, or both.
We also observed that mPCC causes a relatively early deletion when crossed with AD10 TCR-transgenic mice and a later deletion when crossed with the AND TCR-transgenic mice. Since we have not detected a difference in the levels of receptor expression in these two TCR-transgenic mouse lines, the difference in the timing of deletion is probably caused by an affinity difference in the interaction between the TCR and the MHC-peptide complex, the result of a single amino acid difference in the Ix-chain sequences. Thus, the timing of deletion is a function of the avidity of the thymocyte-APC interaction.
Most previous work in TCR-transgenic mice in which negative selection to nominal antigen was examined revealed deletion at a very early DP stage, whereas studies with negative selection induced by endogenous superantigens have revealed deletion late in the life of DP thymocytes, at the transition from DP to SP. The present experiments show that the timing of deletion in part importantly depends on the presentation of the antigenic determinant. The very same TCR-transgenic mice can show an early or a late deletion, depending on antigen presentation and expression levels. Conversely, the very same antigen can cause early or late deletion, depending on the TCR. This is consistent with the avidity model of negative selection.
Taken together, we were able to show that endogenous cellular proteins can gain access to the endocytic processing pathways in vivo to help shape the Th repertoire. The universe of self antigens inducing Th tolerance may therefore be larger than the set of peptides from cell-surface or secreted proteins. Although experiments examining the peptides bound to MHC class II molecules reveal peptides from secreted or membrane-bound proteins (2, 7), these may reflect only the most abundant peptides. In contrast, tolerance induction may require only a small number of peptides presented per cell.
